Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

We aimed to evaluate the correlation among serum parathyroid hormone (PTH) and slow-reflow during primary percutaneous coronary intervention (PCI) and prognosis in patients with ST-segment elevation myocardial infarction (STEMI). A total of 262 patients were enrolled and divided into a slow-reflow group (n=61) and a control group (n=201). PTH was an independent risk factor for slow-reflow (P<0.05), and the regression model had good discrimination and calibration. ROC curve analysis showed that PTH (>= 63.65 pg/ml) had a predictive value for slow-reflow (P<0.001). During the 1-year follow-up, the patients were divided into a PTH-h group (>= 63.65 pg/ml, n=100) and a PTH-l group (<63.65 pg/ml, n=162). Readmission for HF was independently associated with PTH levels (P<0.05). KM survival analysis suggested that PTH-h had a predictive value for MACEs, especially for readmission for HF (P<0.05). PTH levels were associated with slow-reflow during PCI and MACEs during follow-up in patients with STEMI.